Evidence map›Paper›PMID 26942455›Full record

ArticleAIDS research and human retroviruses

Perceptibility and the "Choice Experience": User Sensory Perceptions and Experiences Inform Vaginal Prevention Product Design.

Kate Morrow Guthrie, Shira Dunsiger, Sara E Vargas, Joseph L Fava, Julia G Shaw, Rochelle K Rosen, Patrick F Kiser, E Milu Kojic, David R Friend, David F Katz

Abstract read
In one paragraph

Article in AIDS research and human retroviruses. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kate Morrow Guthrie1 Centers for Behavioral & Preventive Medicine, The Miriam Hospital , Providence, Rhode Island.
Shira Dunsiger1 Centers for Behavioral & Preventive Medicine, The Miriam Hospital , Providence, Rhode Island.
Sara E Vargas1 Centers for Behavioral & Preventive Medicine, The Miriam Hospital , Providence, Rhode Island.
Joseph L Fava1 Centers for Behavioral & Preventive Medicine, The Miriam Hospital , Providence, Rhode Island.
Julia G Shaw1 Centers for Behavioral & Preventive Medicine, The Miriam Hospital , Providence, Rhode Island.
Rochelle K Rosen1 Centers for Behavioral & Preventive Medicine, The Miriam Hospital , Providence, Rhode Island.
Patrick F Kiser4 Department of Bioengineering, University of Utah , Salt Lake City, Utah.
E Milu Kojic5 Immunology Center, The Miriam Hospital , Providence, Rhode Island.
David R Friend7 CONRAD , Arlington, Virginia.
David F Katz8 Departments of Biomedical Engineering & Obstetrics/Gynecology, Duke University , Durham, North Carolina.

Funding

Linking Biophysical Functions of Microbicides to User Perception & AcceptabilityR33MH080591 · NIMH · MIRIAM HOSPITAL · PI GUTHRIE, KATE M · 2008 to 2010
$1.4M
Advancing Reproductive Health: Qualitative Methods & Interdisciplinary MentorshipK24HD062645 · NICHD · MIRIAM HOSPITAL · PI GUTHRIE, KATE M · 2012 to 2016
$689k
NICHD NIH HHS K24 HD062645NIMH NIH HHS R33 MH080591
6 · The paper itself

Abstract

The development of pericoital (on demand) vaginal HIV prevention technologies remains a global health priority. Clinical trials to date have been challenged by nonadherence, leading to an inability to demonstrate product efficacy. The work here provides new methodology and results to begin to address this limitation. We created validated scales that allow users to characterize sensory perceptions and experiences when using vaginal gel formulations. In this study, we sought to understand the user sensory perceptions and experiences (USPEs) that characterize the preferred product experience for each participant. Two hundred four women evaluated four semisolid vaginal formulations using the USPE scales at four randomly ordered formulation evaluation visits. Women were asked to select their preferred formulation experience for HIV prevention among the four formulations evaluated. The scale scores on the Sex-associated USPE scales (e.g., Initial Penetration and Leakage) for each participant's selected formulation were used in a latent class model analysis. Four classes of preferred formulation experiences were identified. Sociodemographic and sexual history variables did not predict class membership; however, four specific scales were significantly related to class: Initial Penetration, Perceived Wetness, Messiness, and Leakage. The range of preferred user experiences represented by the scale scores creates a potential target range for product development, such that products that elicit scale scores that fall within the preferred range may be more acceptable, or tolerable, to the population under study. It is recommended that similar analyses should be conducted with other semisolid vaginal formulations, and in other cultures, to determine product property and development targets.

Indexed as

Patient Acceptance of Health CareAdolescentAdultChemopreventionDrug DiscoveryFemaleHIV InfectionsHumansMiddle AgedPre-Exposure ProphylaxisVaginal Creams, Foams, and JelliesVolunteersYoung AdultVaginal Creams, Foams, and Jelliesadherencedosage formsHIV/STIperceptibilitypreventionproduct choice

Identifiers

PMID26942455
PMCPMC5067921

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.